{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:15:01Z","timestamp":1785946501463,"version":"3.56.0"},"reference-count":124,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arrhythm Electrophysiol Rev"],"abstract":"<jats:p>Over the past several decades, substantial evidence has pointed to the role of the autonomic nervous system in the genesis and maintenance of ventricular arrhythmia. In particular, sympathetic activation has been shown to increase the risk of ventricular arrhythmia, particularly in the context of structural heart diseases, and is a key target of neuromodulatory therapies. Current peripheral sympathetic neuromodulatory approaches include temporary interventions, such as stellate ganglion block, proximal intercostal block, and thoracic epidural anaesthesia, as well as more definitive therapies, such as cardiac sympathetic denervation and renal denervation. Each of these approaches presents distinct strengths and limitations, as well as side effects that warrant careful consideration in clinical practice and highlight the need for more targeted strategies. Emerging interventions focusing on neuropeptide Y, sympathetic afferents ablation, high-frequency block of efferent nerves, and the restoration of sympathetic innervation after MI have shown promising potential. However, further research is needed to evaluate the feasibility and safety of these novel therapies prior to their implementation in patients with cardiovascular diseases.<\/jats:p>","DOI":"10.15420\/aer.2025.24","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T11:17:48Z","timestamp":1766143068000},"source":"Crossref","is-referenced-by-count":5,"title":["Cardiac Sympathetic Innervation and Ventricular Arrhythmias in Structural Heart Disease: Current Peripheral Neuromodulation Therapies and Emerging Therapeutic Targets"],"prefix":"10.15420","author":[{"given":"L\u00e9a","family":"Benabou","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidad de California en Los \u00c1ngeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-9706","authenticated-orcid":false,"given":"Marmar","family":"Vaseghi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidad de California en Los \u00c1ngeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 2014;114:1004\u201321. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.302549; PMID: 24625726. DOI: 10.1161\/CIRCRESAHA.113.302549","DOI":"10.1161\/CIRCRESAHA.113.302549"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Corr PB, Gillis RA. Autonomic neural influences on the dysrhythmias resulting from myocardial infarction. Circ Res 1978;43:1\u20139. https:\/\/doi.org\/10.1161\/01.res.43.1.1; PMID: 350450. DOI: 10.1161\/01.RES.43.1.1","DOI":"10.1161\/01.RES.43.1.1"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Jardine DL, Charles CJ, Ashton RK, et al. Increased cardiac sympathetic nerve activity following acute myocardial infarction in a sheep model. J Physiol 2005;565:325\u201333. https:\/\/doi.org\/10.1113\/jphysiol.2004.082198; PMID: 15774526. DOI: 10.1113\/jphysiol.2004.082198","DOI":"10.1113\/jphysiol.2004.082198"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(97)11144-8; PMID: 9482439. DOI: 10.1016\/S0140-6736(97)11144-8","DOI":"10.1016\/S0140-6736(97)11144-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ma R, Zucker IH, Wang W. Central gain of the cardiac sympathetic afferent reflex in dogs with heart failure. Am J Physiol 1997;273:H2664\u201371. https:\/\/doi.org\/10.1152\/ajpheart.1997.273.6.H2664; PMID: 9435602. DOI: 10.1152\/ajpheart.1997.273.6.H2664","DOI":"10.1152\/ajpheart.1997.273.6.H2664"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"van Weperen VYH, Ripplinger CM, Vaseghi M. Autonomic control of ventricular function in health and disease: current state of the art. Clin Auton Res 2023;33:491\u2013517. https:\/\/doi.org\/10.1007\/s10286-023-00948-8; PMID: 37166736. DOI: 10.1007\/s10286-023-00948-8","DOI":"10.1007\/s10286-023-00948-8"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Zipes DP, Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm 2006;3:108\u201313. https:\/\/doi.org\/10.1016\/j.hrthm.2005.09.021; PMID: 16399065. DOI: 10.1016\/j.hrthm.2005.09.021","DOI":"10.1016\/j.hrthm.2005.09.021"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962;267:650\u20134. https:\/\/doi.org\/10.1056\/NEJM196209272671305; PMID: 13878934. DOI: 10.1056\/NEJM196209272671305","DOI":"10.1056\/NEJM196209272671305"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996;94:690\u20137. https:\/\/doi.org\/10.1161\/01.cir.94.4.690; PMID: 8772689. DOI: 10.1161\/01.CIR.94.4.690","DOI":"10.1161\/01.CIR.94.4.690"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kalla M, Hao G, Tapoulal N, et al. The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J 2020;41:2168\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehz852; PMID: 31834357. DOI: 10.1093\/eurheartj\/ehz852","DOI":"10.1093\/eurheartj\/ehz852"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 1994;15:454\u201361. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a060526; PMID: 8070470. DOI: 10.1093\/oxfordjournals.eurheartj.a060526","DOI":"10.1093\/oxfordjournals.eurheartj.a060526"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Han S, Kobayashi K, Joung B, et al. Electroanatomic remodeling of the left stellate ganglion after myocardial infarction. J Am Coll Cardiol 2012;59:954\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2011.11.030; PMID: 22381432. DOI: 10.1016\/j.jacc.2011.11.030","DOI":"10.1016\/j.jacc.2011.11.030"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ajijola OA, Hoover DB, Simerly TM, et al. Inflammation, oxidative stress, and glial cell activation characterize stellate ganglia from humans with electrical storm. JCI Insight 2017;2:e94715. https:\/\/doi.org\/10.1172\/jci.insight.94715; PMID: 28931760. DOI: 10.1172\/jci.insight.94715","DOI":"10.1172\/jci.insight.94715"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Barrett MS, Bauer TC, Li MH, et al. Ischemia\u2013reperfusion myocardial infarction induces remodeling of left cardiac-projecting stellate ganglia neurons. Am J Physiol Heart Circ Physiol 2024;326:H166\u201379. https:\/\/doi.org\/10.1152\/ajpheart.00582.2023; PMID: 37947434. DOI: 10.1152\/ajpheart.00582.2023","DOI":"10.1152\/ajpheart.00582.2023"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Salavatian S, Hoang JD, Yamaguchi N, et al. Myocardial infarction reduces cardiac nociceptive neurotransmission through the vagal ganglia. JCI Insight 2022;7:e155747. https:\/\/doi.org\/10.1172\/jci.insight.155747; PMID: 35015733. DOI: 10.1172\/jci.insight.155747","DOI":"10.1172\/jci.insight.155747"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Devarajan A, Wang K, Lokhandwala ZA, et al. Myocardial infarction causes sex-dependent dysfunction in vagal sensory glutamatergic neurotransmission that is mitigated by 17\u03b2-estradiol. JCI Insight 2024;9:e181042. https:\/\/doi.org\/10.1172\/jci.insight.181042; PMID: 38885308. DOI: 10.1172\/jci.insight.181042","DOI":"10.1172\/jci.insight.181042"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"van Weperen VYH, Vaseghi M. Cardiac vagal afferent neurotransmission in health and disease: review and knowledge gaps. Front Neurosci 2023;17:1192188. https:\/\/doi.org\/10.3389\/fnins.2023.1192188; PMID: 37351426. DOI: 10.3389\/fnins.2023.1192188","DOI":"10.3389\/fnins.2023.1192188"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cao JM, Chen LS, KenKnight BH, et al. Nerve sprouting and sudden cardiac death. Circ Res 2000;86:816\u201321. https:\/\/doi.org\/10.1161\/01.res.86.7.816; PMID: 10764417. DOI: 10.1161\/01.RES.86.7.816","DOI":"10.1161\/01.RES.86.7.816"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Vracko R, Thorning D, Frederickson RG. Nerve fibers in human myocardial scars. Hum Pathol 1991;22:138\u201346. https:\/\/doi.org\/10.1016\/0046-8177(91)90035-n; PMID: 1705914. DOI: 10.1016\/0046-8177(91)90035-N","DOI":"10.1016\/0046-8177(91)90035-N"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Inoue H, Zipes DP. Time course of denervation of efferent sympathetic and vagal nerves after occlusion of the coronary artery in the canine heart. Circ Res 1988;62:1111\u201320. https:\/\/doi.org\/10.1161\/01.res.62.6.1111; PMID: 3383360. DOI: 10.1161\/01.RES.62.6.1111","DOI":"10.1161\/01.RES.62.6.1111"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Kammerling JJ, Green FJ, Watanabe AM, et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation 1987;76:383\u201393. https:\/\/doi.org\/10.1161\/01.cir.76.2.383; PMID: 3038369. DOI: 10.1161\/01.CIR.76.2.383","DOI":"10.1161\/01.CIR.76.2.383"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987;75:877\u201387. https:\/\/doi.org\/10.1161\/01.cir.75.4.877; PMID: 3829345. DOI: 10.1161\/01.CIR.75.4.877","DOI":"10.1161\/01.CIR.75.4.877"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Vaseghi M, Lux RL, Mahajan A, Shivkumar K. Sympathetic stimulation increases dispersion of repolarization in humans with myocardial infarction. Am J Physiol Heart Circ Physiol 2012;302:h1838\u201346. https:\/\/doi.org\/10.1152\/ajpheart.01106.2011; PMID: 22345568. DOI: 10.1152\/ajpheart.01106.2011","DOI":"10.1152\/ajpheart.01106.2011"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Cao JM, Fishbein MC, Han JB, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000;101:1960\u20139. https:\/\/doi.org\/10.1161\/01.cir.101.16.1960; PMID: 10779463. DOI: 10.1161\/01.CIR.101.16.1960","DOI":"10.1161\/01.CIR.101.16.1960"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Boogers MJ, Borleffs CJW, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2009.12.066; PMID: 20538172. DOI: 10.1016\/j.jacc.2009.12.066","DOI":"10.1016\/j.jacc.2009.12.066"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Fallavollita JA, Heavey BM, Luisi AJ Jr, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.096; PMID: 24076296. DOI: 10.1016\/j.jacc.2013.07.096","DOI":"10.1016\/j.jacc.2013.07.096"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Rizas KD, Hamm W, K\u00e4\u00e4b S, et al. Periodic repolarisation dynamics: a natural probe of the ventricular response to sympathetic activation. Arrhythm Electrophysiol Rev 2016;5:31\u20136. https:\/\/doi.org\/10.15420\/aer.2015:30:2; PMID: 27403291. DOI: 10.15420\/aer.2015:30:2","DOI":"10.15420\/aer.2015:30:2"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wang W, Schultz HD, Ma R. Cardiac sympathetic afferent sensitivity is enhanced in heart failure. Am J Physiol 1999;277:H812\u20137. https:\/\/doi.org\/10.1152\/ajpheart.1999.277.2.H812; PMID: 10444509. DOI: 10.1152\/ajpheart.1999.277.2.H812","DOI":"10.1152\/ajpheart.1999.277.2.H812"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Nakamura K, Ajijola OA, Aliotta E, et al. Pathological effects of chronic myocardial infarction on peripheral neurons mediating cardiac neurotransmission. Auton Neurosci 2016;197:34\u201340. https:\/\/doi.org\/10.1016\/j.autneu.2016.05.001; PMID: 27209472. DOI: 10.1016\/j.autneu.2016.05.001","DOI":"10.1016\/j.autneu.2016.05.001"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kanazawa H, Ieda M, Kimura K, et al. Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest 2010;120:408\u201321. https:\/\/doi.org\/10.1172\/JCI39778; PMID: 20051627. DOI: 10.1172\/JCI39778","DOI":"10.1172\/JCI39778"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Olivas A, Gardner RT, Wang L, et al. Myocardial infarction causes transient cholinergic transdifferentiation of cardiac sympathetic nerves via gp130. J Neurosci 2016;36:479\u201388. https:\/\/doi.org\/10.1523\/JNEUROSCI.3556-15.2016; PMID: 26758839. DOI: 10.1523\/JNEUROSCI.3556-15.2016","DOI":"10.1523\/JNEUROSCI.3556-15.2016"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wang L, Olivas A, Francis Stuart SD, et al. Cardiac sympathetic nerve transdifferentiation reduces action potential heterogeneity after myocardial infarction. Am J Physiol Heart Circ Physiol 2020;318:H558\u201365. https:\/\/doi.org\/10.1152\/ajpheart.00412.2019; PMID: 31975627. DOI: 10.1152\/ajpheart.00412.2019","DOI":"10.1152\/ajpheart.00412.2019"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295\u2013302. https:\/\/doi.org\/10.1001\/jama.283.10.1295; PMID: 10714728. DOI: 10.1001\/jama.283.10.1295","DOI":"10.1001\/jama.283.10.1295"},{"key":"ref33","unstructured":"Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651\u20138. https:\/\/doi.org\/10.1056\/NEJM200105313442201; PMID: 11386263."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501; PMID: 2057034. DOI: 10.1056\/NEJM199108013250501","DOI":"10.1056\/NEJM199108013250501"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670\u20136. https:\/\/doi.org\/10.1056\/NEJM199512213332503; PMID: 7477219. DOI: 10.1056\/NEJM199512213332503","DOI":"10.1056\/NEJM199512213332503"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Baldi E, Conte G, Zeppenfeld K, et al. Contemporary management of ventricular electrical storm in Europe: results of a European Heart Rhythm Association survey. Europace 2023;25:1277\u201383. https:\/\/doi.org\/10.1093\/europace\/euac151; PMID: 36196613. DOI: 10.1093\/europace\/euac151","DOI":"10.1093\/europace\/euac151"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Yanowitz F, Preston JB, Abildskov JA. Functional distribution of right and left stellate innervation to the ventricles. Production of neurogenic electrocardiographic changes by unilateral alteration of sympathetic tone. Circ Res 1966;18:416\u201328. https:\/\/doi.org\/10.1161\/01.res.18.4.416; PMID: 4952701. DOI: 10.1161\/01.RES.18.4.416","DOI":"10.1161\/01.RES.18.4.416"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Schwartz PJ. Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol 2014;11:346\u201353. https:\/\/doi.org\/10.1038\/nrcardio.2014.19; PMID: 24614115. DOI: 10.1038\/nrcardio.2014.19","DOI":"10.1038\/nrcardio.2014.19"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Vaseghi M, Yamakawa K, Sinha A, et al. Modulation of regional dispersion of repolarization and T-peak to T-end interval by the right and left stellate ganglia. Am J Physiol Heart Circ Physiol 2013;305:h1020\u201330. https:\/\/doi.org\/10.1152\/ajpheart.00056.2013; PMID: 23893168. DOI: 10.1152\/ajpheart.00056.2013","DOI":"10.1152\/ajpheart.00056.2013"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Chouairi F, Rajkumar K, Benak A, et al. A multicenter study of stellate ganglion block as a temporizing treatment for refractory ventricular arrhythmias. JACC Clin Electrophysiol 2024;10:750\u20138. https:\/\/doi.org\/10.1016\/j.jacep.2023.12.012; PMID: 38363278. DOI: 10.1016\/j.jacep.2023.12.012","DOI":"10.1016\/j.jacep.2023.12.012"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Tian Y, Wittwer ED, Kapa S, et al. Effective use of percutaneous stellate ganglion blockade in patients with electrical storm. Circ Arrhythm Electrophysiol 2019;12:e007118. https:\/\/doi.org\/10.1161\/CIRCEP.118.007118; PMID: 31514529. DOI: 10.1161\/CIRCEP.118.007118","DOI":"10.1161\/CIRCEP.118.007118"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Fudim M, Qadri YJ, Waldron NH, et al. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias. JACC Clin Electrophysiol 2020;6:562\u201371. https:\/\/doi.org\/10.1016\/j.jacep.2019.12.017; PMID: 32439042. DOI: 10.1016\/j.jacep.2019.12.017","DOI":"10.1016\/j.jacep.2019.12.017"},{"key":"ref43","unstructured":"Savastano S, Baldi E, Compagnoni S, et al. Electrical storm treatment by percutaneous stellate ganglion block: the STAR study. Eur Heart J 2024;45:823\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehae021; PMID: 38289867."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Patel RA, Condrey JM, George RM, et al. Stellate ganglion block catheters for refractory electrical storm: a retrospective cohort and care pathway. Reg Anesth Pain Med 2023;48:224\u20138. https:\/\/doi.org\/10.1136\/rapm-2022-104172; PMID: 36725213. DOI: 10.1136\/rapm-2022-104172","DOI":"10.1136\/rapm-2022-104172"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Sanghai S, Abbott NJ, Dewland TA, et al. Stellate ganglion blockade with continuous infusion versus single injection for treatment of ventricular arrhythmia storm. JACC Clin Electrophysiol 2021;7:452\u201360. https:\/\/doi.org\/10.1016\/j.jacep.2020.09.032; PMID: 33358672. DOI: 10.1016\/j.jacep.2020.09.032","DOI":"10.1016\/j.jacep.2020.09.032"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Dusi V, Angelini F, Baldi E, et al. Continuous stellate ganglion block for ventricular arrhythmias: case series, systematic review, and differences from thoracic epidural anaesthesia. Europace 2024;26:euae074. https:\/\/doi.org\/10.1093\/europace\/euae074; PMID: 38531027. DOI: 10.1093\/europace\/euae074","DOI":"10.1093\/europace\/euae074"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Nonoguchi NM, Adachi M, Nogami A, et al. Stellate ganglion phototherapy using low-level laser: a novel rescue therapy for patients with refractory ventricular arrhythmias. JACC Clin Electrophysiol 2021;7:1297\u2013308. https:\/\/doi.org\/10.1016\/j.jacep.2021.04.015; PMID: 34217659. DOI: 10.1016\/j.jacep.2021.04.015","DOI":"10.1016\/j.jacep.2021.04.015"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Sato T, Kamada R, Koizumi T, et al. Refractory ventricular tachycardia in a patient with a left ventricular assist device successfully treated with stellate ganglion phototherapy. Can J Cardiol 2020;36:1977.e1\u20133. https:\/\/doi.org\/10.1016\/j.cjca.2020.08.002; PMID: 32798700. DOI: 10.1016\/j.cjca.2020.08.002","DOI":"10.1016\/j.cjca.2020.08.002"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Takahashi K, Egami Y, Nishino M, Tanouchi J. Clinical impact of stellate ganglion phototherapy on ventricular tachycardia storm requiring mechanical circulatory support devices: a case report. Eur Heart J Case Rep 2024;8:ytae177. https:\/\/doi.org\/10.1093\/ehjcr\/ytae177; PMID: 38690554. DOI: 10.1093\/ehjcr\/ytae177","DOI":"10.1093\/ehjcr\/ytae177"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Markman TM, Pothineni NVK, Zghaib T, et al. Effect of transcutaneous magnetic stimulation in patients with ventricular tachycardia storm: a randomized clinical trial. JAMA Cardiol 2022;7:445\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2021.6000; PMID: 35171197. DOI: 10.1001\/jamacardio.2021.6000","DOI":"10.1001\/jamacardio.2021.6000"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Narziev B, Yakubov A, Hamraev R, et al. A case of successful percutaneous ethanol stellate ganglion block on ventricular tachycardia storm. J Cardiol Cases 2021;23:234\u20137. https:\/\/doi.org\/10.1016\/j.jccase.2020.11.015; PMID: 33995705. DOI: 10.1016\/j.jccase.2020.11.015","DOI":"10.1016\/j.jccase.2020.11.015"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Chatzidou S, Kontogiannis C, Tampakis K, et al. Cryoablation of stellate ganglion for the management of electrical storm: the first reported case. Europace 2021;23:1105. https:\/\/doi.org\/10.1093\/europace\/euab006; PMID: 33550397. DOI: 10.1093\/europace\/euab006","DOI":"10.1093\/europace\/euab006"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Rao BH, Lokre A, Patnala N, Padmanabhan TNC. Stellate ganglion ablation by conventional radiofrequency in patients with electrical storm. Europace 2023;25:euad290. https:\/\/doi.org\/10.1093\/europace\/euad290; PMID: 37738408. DOI: 10.1093\/europace\/euad290","DOI":"10.1093\/europace\/euad290"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Hayase J, Vampola S, Ahadian F, et al. Comparative efficacy of stellate ganglion block with bupivacaine vs pulsed radiofrequency in a patient with refractory ventricular arrhythmias. J Clin Anesth 2016;31:162\u20135. https:\/\/doi.org\/10.1016\/j.jclinane.2016.01.026; PMID: 27185701. DOI: 10.1016\/j.jclinane.2016.01.026","DOI":"10.1016\/j.jclinane.2016.01.026"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Batnyam U, Vlassakov KV, Halawa A, et al. Safety and efficacy of ultrasound-guided sympathetic blockade by proximal intercostal block in electrical storm patients. JACC Clin Electrophysiol 2024;10:734\u201346. DOI: 10.1016\/j.jacep.2023.12.006","DOI":"10.1016\/j.jacep.2023.12.006"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Zinboonyahgoon N, Luksanapruksa P, Piyaselakul S, et al. The ultrasound-guided proximal intercostal block: anatomical study and clinical correlation to analgesia for breast surgery. BMC Anesthesiol 2019;19:94. https:\/\/doi.org\/10.1186\/s12871-019-0762-2; PMID: 31164083. DOI: 10.1186\/s12871-019-0762-2","DOI":"10.1186\/s12871-019-0762-2"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Bourke T, Vaseghi M, Michowitz Y, et al. Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. Circulation 2010;121:2255\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.929703; PMID: 20479150. DOI: 10.1161\/CIRCULATIONAHA.109.929703","DOI":"10.1161\/CIRCULATIONAHA.109.929703"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Do DH, Bradfield J, Ajijola OA, et al. Thoracic epidural anesthesia can be effective for the short-term management of ventricular tachycardia storm. J Am Heart Assoc 2017;6:e007080. https:\/\/doi.org\/10.1161\/JAHA.117.007080; PMID: 29079570. DOI: 10.1161\/JAHA.117.007080","DOI":"10.1161\/JAHA.117.007080"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Hoang JD, van Weperen VYH, Kang KW, et al. Antiarrhythmic mechanisms of epidural blockade after myocardial infarction. Circ Res 2024;135:e57\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.324058; PMID: 38939925. DOI: 10.1161\/CIRCRESAHA.123.324058","DOI":"10.1161\/CIRCRESAHA.123.324058"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Dusi V, Gornbein J, Do DH, et al. Arrhythmic risk profile and outcomes of patients undergoing cardiac sympathetic denervation for recurrent monomorphic ventricular tachycardia after ablation. J Am Heart Assoc 2021;10:e018371. https:\/\/doi.org\/10.1161\/JAHA.120.018371; PMID: 33441022. DOI: 10.1161\/JAHA.120.018371","DOI":"10.1161\/JAHA.120.018371"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Vaseghi M, Barwad P, Malavassi Corrales FJ, et al. Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol 2017;69:3070\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.035; PMID: 28641796. DOI: 10.1016\/j.jacc.2017.04.035","DOI":"10.1016\/j.jacc.2017.04.035"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Irie T, Yamakawa K, Hamon D, et al. Cardiac sympathetic innervation via middle cervical and stellate ganglia and antiarrhythmic mechanism of bilateral stellectomy. Am J Physiol Heart Circ Physiol 2017;312:H392\u2013405. https:\/\/doi.org\/10.1152\/ajpheart.00644.2016; PMID: 28011590. DOI: 10.1152\/ajpheart.00644.2016","DOI":"10.1152\/ajpheart.00644.2016"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Assis FR, Sharma A, Shah R, et al. Long-term outcomes of bilateral cardiac sympathetic denervation for refractory ventricular tachycardia. JACC Clin Electrophysiol 2021;7:463\u201370. https:\/\/doi.org\/10.1016\/j.jacep.2021.02.003; PMID: 33812839. DOI: 10.1016\/j.jacep.2021.02.003","DOI":"10.1016\/j.jacep.2021.02.003"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Sridharan A, Tang A, Sorg JM, et al. Effect of bilateral cardiac sympathetic denervation on burden of premature ventricular contractions. Circ Arrhythm Electrophysiol 2023;16:e011546. https:\/\/doi.org\/10.1161\/CIRCEP.122.011546; PMID: 36916281. DOI: 10.1161\/CIRCEP.122.011546","DOI":"10.1161\/CIRCEP.122.011546"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Ahmed A, Charate R, Bawa D, et al. Bilateral cardiac sympathetic denervation for refractory multifocal premature ventricular contractions in patients with nonischemic cardiomyopathy. JACC Clin Electrophysiol 2024;10:31\u20139. https:\/\/doi.org\/10.1016\/j.jacep.2023.09.014; PMID: 37943190. DOI: 10.1016\/j.jacep.2023.09.014","DOI":"10.1016\/j.jacep.2023.09.014"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm 2014;11:360\u20136. https:\/\/doi.org\/10.1016\/j.hrthm.2013.11.028; PMID: 24291775. DOI: 10.1016\/j.hrthm.2013.11.028","DOI":"10.1016\/j.hrthm.2013.11.028"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2015;8:1151\u20138. https:\/\/doi.org\/10.1161\/CIRCEP.115.003159; PMID: 26224781. DOI: 10.1161\/CIRCEP.115.003159","DOI":"10.1161\/CIRCEP.115.003159"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Curtis B, VanAken G, Al-Sadawi M, et al. Safety and outcomes of surgical cardiac sympathetic denervation when used as salvage therapy among high-risk patients with refractory ventricular arrhythmias. J Interv Card Electrophysiol 2025;68:411\u20133. https:\/\/doi.org\/10.1007\/s10840-024-01874-z; PMID: 39007967. DOI: 10.1007\/s10840-024-01874-z","DOI":"10.1007\/s10840-024-01874-z"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Cauti FM, Rossi P, Bianchi S, et al. Modified sympathicotomy in patients with refractory ventricular tachycardia and structural heart disease: a single-center experience. J Interv Card Electrophysiol 2025;68:391\u20139. https:\/\/doi.org\/10.1007\/s10840-023-01706-6; PMID: 38040851. DOI: 10.1007\/s10840-023-01706-6","DOI":"10.1007\/s10840-023-01706-6"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Weiss ML, Chowdhury SI. The renal afferent pathways in the rat: a pseudorabies virus study. Brain Res 1998;812:227\u201341. https:\/\/doi.org\/10.1016\/s0006-8993(98)00950-0; PMID: 9813344. DOI: 10.1016\/S0006-8993(98)00950-0","DOI":"10.1016\/S0006-8993(98)00950-0"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Bradfield JS, Vaseghi M, Shivkumar K. Renal denervation for refractory ventricular arrhythmias. Trends Cardiovasc Med 2014;24:206\u201313. https:\/\/doi.org\/10.1016\/j.tcm.2014.05.006; PMID: 25017919. DOI: 10.1016\/j.tcm.2014.05.006","DOI":"10.1016\/j.tcm.2014.05.006"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Hu W, Tu H, Wadman MC, et al. Renal denervation achieves its antiarrhythmic effect through attenuating macrophage activation and neuroinflammation in stellate ganglia in chronic heart failure. Cardiovasc Res 2025;120:2420\u201333. https:\/\/doi.org\/10.1093\/cvr\/cvae196; PMID: 39321201. DOI: 10.1093\/cvr\/cvae196","DOI":"10.1093\/cvr\/cvae196"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Zhang WH, Zhou QN, Lu YM, et al. Renal denervation reduced ventricular arrhythmia after myocardial infarction by inhibiting sympathetic activity and remodeling. J Am Heart Assoc 2018;7:e009938. https:\/\/doi.org\/10.1161\/JAHA.118.009938; PMID: 30371294. DOI: 10.1161\/JAHA.118.009938","DOI":"10.1161\/JAHA.118.009938"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Hori Y, Temma T, Wooten C, et al. Aorticorenal ganglion as a novel target for renal neuromodulation. Heart Rhythm 2021;18:1745\u201357. https:\/\/doi.org\/10.1016\/j.hrthm.2021.06.1192; PMID: 34182169. DOI: 10.1016\/j.hrthm.2021.06.1192","DOI":"10.1016\/j.hrthm.2021.06.1192"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Linz D, Wirth K, Ukena C, et al. Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm 2013;10:1525\u201330. https:\/\/doi.org\/10.1016\/j.hrthm.2013.07.015; PMID: 23851058. DOI: 10.1016\/j.hrthm.2013.07.015","DOI":"10.1016\/j.hrthm.2013.07.015"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ukena C, Mahfoud F, Ewen S, et al. Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol 2016;105:873\u20139. https:\/\/doi.org\/10.1007\/s00392-016-1012-y; PMID: 27364940. DOI: 10.1007\/s00392-016-1012-y","DOI":"10.1007\/s00392-016-1012-y"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Armaganijan LV, Staico R, Moreira DAR, et al. 6-month outcomes in patients with implantable cardioverter-defibrillators undergoing renal sympathetic denervation for the treatment of refractory ventricular arrhythmias. JACC Cardiovasc Interv 2015;8:984\u201390. https:\/\/doi.org\/10.1016\/j.jcin.2015.03.012; PMID: 26088516. DOI: 10.1016\/j.jcin.2015.03.012","DOI":"10.1016\/j.jcin.2015.03.012"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Hawson J, Harmer JA, Cowan M, et al. Renal denervation for the management of refractory ventricular arrhythmias: a systematic review. JACC Clin Electrophysiol 2021;7:100\u20138. https:\/\/doi.org\/10.1016\/j.jacep.2020.07.019; PMID: 33478701. DOI: 10.1016\/j.jacep.2020.07.019","DOI":"10.1016\/j.jacep.2020.07.019"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Bradfield JS, Hayase J, Liu K, et al. Renal denervation as adjunctive therapy to cardiac sympathetic denervation for ablation refractory ventricular tachycardia. Heart Rhythm 2020;17:220\u20137. https:\/\/doi.org\/10.1016\/j.hrthm.2019.09.016; PMID: 31539629. DOI: 10.1016\/j.hrthm.2019.09.016","DOI":"10.1016\/j.hrthm.2019.09.016"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911\u20137. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.163014; PMID: 21403086. DOI: 10.1161\/HYPERTENSIONAHA.110.163014","DOI":"10.1161\/HYPERTENSIONAHA.110.163014"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(10)62039-9; PMID: 21093036. DOI: 10.1016\/S0140-6736(10)62039-9","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"ref82","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa1402670; PMID: 24678939."},{"key":"ref83","unstructured":"Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(18)31082-1; PMID: 29803590."},{"key":"ref84","unstructured":"Azizi M, Saxena M, Wang Y et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II Randomized Clinical Trial. J AM Med Assoc 2023;329:651\u201361. https:\/\/doi.org\/10.1001\/jama.2023.8136; PMID: 36853250."},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Pathak A, Rudolph U, Sexena M et al. Alcohol-mediated renal denervation in patients with hypertension in the absence of medications. EuroIntervention 2023;19:602\u201311. https:\/\/doi.org\/10.4244\/EIJ-D-23-00088; PMID: 37427416. DOI: 10.4244\/EIJ-D-23-00088","DOI":"10.4244\/EIJ-D-23-00088"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Tzafriri AR, Keating JH, Markham PM, et al. Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Sci Transl Med 2015;7:285ra65. https:\/\/doi.org\/10.1126\/scitranslmed.aaa3236; PMID: 25925684. DOI: 10.1126\/scitranslmed.aaa3236","DOI":"10.1126\/scitranslmed.aaa3236"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Burnstock G. Autonomic neurotransmission: 60 years since Sir Henry Dale. Annu Rev Pharmacol Toxicol 2009;49:1\u201330. https:\/\/doi.org\/10.1146\/annurev.pharmtox.052808.102215; PMID: 18834312. DOI: 10.1146\/annurev.pharmtox.052808.102215","DOI":"10.1146\/annurev.pharmtox.052808.102215"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"van Weperen VYH, Hoang JD, Jani NR, et al. Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of beta-adrenergic receptors. J Physiol 2025;603:1911\u201321. https:\/\/doi.org\/10.1113\/JP285945; PMID: 38352977. DOI: 10.1113\/JP285945","DOI":"10.1113\/JP285945"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Herring N, Lokale MN, Danson EJ, et al. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 2008;44:477\u201385. https:\/\/doi.org\/10.1016\/j.yjmcc.2007.10.001; PMID: 17996892. DOI: 10.1016\/j.yjmcc.2007.10.001","DOI":"10.1016\/j.yjmcc.2007.10.001"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Heredia Mdel P, Delgado C, Pereira L, et al. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol 2005;38:205\u201312. https:\/\/doi.org\/10.1016\/j.yjmcc.2004.11.001; PMID: 15623437. DOI: 10.1016\/j.yjmcc.2004.11.001","DOI":"10.1016\/j.yjmcc.2004.11.001"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Hoang JD, Salavatian S, Yamaguchi N, et al. Cardiac sympathetic activation circumvents high-dose beta blocker therapy in part through release of neuropeptide Y. JCI Insight 2020;5:e135519. https:\/\/doi.org\/10.1172\/jci.insight.135519; PMID: 32493842. DOI: 10.1172\/jci.insight.135519","DOI":"10.1172\/jci.insight.135519"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Bloxsom R, Liu K, Handford C, et al. The cardiac sympathetic co-transmitter neuropeptide-Y is pro-arrhythmic in human cardiomyocytes by lengthening activation-recovery interval. Eur Heart J 2024;45(Suppl 1):ehae666.3774. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.3774. DOI: 10.1093\/eurheartj\/ehae666.3774","DOI":"10.1093\/eurheartj\/ehae666.3774"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Herring N, Kalla M, Dall\u2019Armellina E, et al. Pro-arrhythmic effects of the cardiac sympathetic co-transmitter, neuropeptide-Y, during ischemia\u2013reperfusion and ST elevation myocardial infarction. FASEB J 2016;30:756.2. https:\/\/doi.org\/10.1096\/fasebj.30.1_supplement.756.2. DOI: 10.1096\/fasebj.30.1_supplement.756.2","DOI":"10.1096\/fasebj.30.1_supplement.756.2"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Tang J, Liu C, Wang Z, et al. Neuropeptide Y as a prognostic biomarker in electrical storm. JACC Clin Electrophysiol 2025;11:655\u201363. https:\/\/doi.org\/10.1016\/j.jacep.2024.11.021; PMID: 39918460. DOI: 10.1016\/j.jacep.2024.11.021","DOI":"10.1016\/j.jacep.2024.11.021"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Gibbs T, Tapoulal N, Shanmuganathan M, et al. Neuropeptide-Y levels in ST-segment-elevation myocardial infarction: relationship with coronary microvascular function, heart failure, and mortality. J Am Heart Assoc 2022;11:e024850. https:\/\/doi.org\/10.1161\/JAHA.121.024850; PMID: 35766271. DOI: 10.1161\/JAHA.121.024850","DOI":"10.1161\/JAHA.121.024850"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Herring N, Tapoulal N, Kalla M, et al. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J 2019;40:1920\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehz115; PMID: 30859228. DOI: 10.1093\/eurheartj\/ehz115","DOI":"10.1093\/eurheartj\/ehz115"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Cuculi F, Herring N, De Caterina AR, et al. Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction. Heart 2013;99:1198\u2013203. https:\/\/doi.org\/10.1136\/heartjnl-2012-303443; PMID: 23403409. DOI: 10.1136\/heartjnl-2012-303443","DOI":"10.1136\/heartjnl-2012-303443"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Van Weperen VY, Hoang JD, Jani NR, et al. Electrophysiological effects of sympathoexcitation are mitigated by blockade of neuropeptide Y Y2 receptors on cardiac parasympathetic nerve terminals. Circulation 2022;146(Suppl 1):Abstract 11494. https:\/\/doi.org\/10.1161\/circ.146.suppl_1.11494. DOI: 10.1161\/circ.146.suppl_1.11494","DOI":"10.1161\/circ.146.suppl_1.11494"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Jani NR, van Weperen VYH, Ayagama T, et al. Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation. Cardiovasc Res 2025. In press. https:\/\/doi.org\/10.1093\/cvr\/cvaf180 2025. DOI: 10.1093\/cvr\/cvaf180","DOI":"10.1093\/cvr\/cvaf180"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Pan HL, Chen SR. Sensing tissue ischemia: another new function for capsaicin receptors? Circulation 2004;110:1826\u201331. https:\/\/doi.org\/10.1161\/01.CIR.0000142618.20278.7A; PMID: 15364816. DOI: 10.1161\/01.CIR.0000142618.20278.7A","DOI":"10.1161\/01.CIR.0000142618.20278.7A"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Uchida Y, Murao S. Bradykinin-induced excitation of afferent cardiac sympathetic nerve fibers. Jpn Heart J 1974;15:84\u201391. https:\/\/doi.org\/10.1536\/ihj.15.84; PMID: 4545923. DOI: 10.1536\/ihj.15.84","DOI":"10.1536\/ihj.15.84"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Schultz HD, Ustinova EE. Capsaicin receptors mediate free radical-induced activation of cardiac afferent endings. Cardiovasc Res 1998;38:348\u201355. https:\/\/doi.org\/10.1016\/s0008-6363(98)00031-5; PMID: 9709395. DOI: 10.1016\/S0008-6363(98)00031-5","DOI":"10.1016\/S0008-6363(98)00031-5"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Yoshie K, Rajendran PS, Massoud L, et al. Cardiac TRPV1 afferent signaling promotes arrhythmogenic ventricular remodeling after myocardial infarction. JCI Insight 2020;5:e124477. https:\/\/doi.org\/10.1172\/jci.insight.124477; PMID: 31846438. DOI: 10.1172\/jci.insight.124477","DOI":"10.1172\/jci.insight.124477"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Wang HJ, Wang W, Cornish KG, et al. Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure. Hypertension 2014;64:745\u201355. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03699; PMID: 24980663. DOI: 10.1161\/HYPERTENSIONAHA.114.03699","DOI":"10.1161\/HYPERTENSIONAHA.114.03699"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Wu Y, Hu Z, Wang D, et al. Resiniferatoxin reduces ventricular arrhythmias in heart failure via selectively blunting cardiac sympathetic afferent projection into spinal cord in rats. Eur J Pharmacol 2020;867:172836. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172836; PMID: 31811858. DOI: 10.1016\/j.ejphar.2019.172836","DOI":"10.1016\/j.ejphar.2019.172836"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Yamaguchi T, Salavatian S, Kuwabara Y, et al. Thoracic dorsal root ganglion application of resiniferatoxin reduces myocardial ischemia-induced ventricular arrhythmias. Biomedicines 2023;11:2720. https:\/\/doi.org\/10.3390\/biomedicines11102720; PMID: 37893094. DOI: 10.3390\/biomedicines11102720","DOI":"10.3390\/biomedicines11102720"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"van Weperen V, Hoang J, Chan C, et al. Bs-469619-001 Spinal afferent denervation ameliorates pathological autonomic remodeling and reduces ventricular arrhythmias after chronic myocardial infarction. Heart Rhythm 2024;21(Suppl):S51\u20132. https:\/\/doi.org\/10.1016\/j.hrthm.2024.03.361. DOI: 10.1016\/j.hrthm.2024.03.361","DOI":"10.1016\/j.hrthm.2024.03.361"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Fjordbakk CT, Miranda JA, Sokal D, et al. Feasibility of kilohertz frequency alternating current neuromodulation of carotid sinus nerve activity in the pig. Sci Rep 2019;9:18136. https:\/\/doi.org\/10.1038\/s41598-019-53566-8; PMID: 31792232. DOI: 10.1038\/s41598-019-53566-8","DOI":"10.1038\/s41598-019-53566-8"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Hadaya J, Buckley U, Gurel NZ, et al. Scalable and reversible axonal neuromodulation of the sympathetic chain for cardiac control. Am J Physiol Heart Circ Physiol 2022;322:H105\u201315. https:\/\/doi.org\/10.1152\/ajpheart.00568.2021; PMID: 34860595. DOI: 10.1152\/ajpheart.00568.2021","DOI":"10.1152\/ajpheart.00568.2021"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Buckley U, Chui RW, Rajendran PS, et al. Bioelectronic neuromodulation of the paravertebral cardiac efferent sympathetic outflow and its effect on ventricular electrical indices. Heart Rhythm 2017;14:1063\u201370. https:\/\/doi.org\/10.1016\/j.hrthm.2017.02.020; PMID: 28219848. DOI: 10.1016\/j.hrthm.2017.02.020","DOI":"10.1016\/j.hrthm.2017.02.020"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Chui RW, Buckley U, Rajendran PS, et al. Bioelectronic block of paravertebral sympathetic nerves mitigates post-myocardial infarction ventricular arrhythmias. Heart Rhythm 2017;14:1665\u201372. https:\/\/doi.org\/10.1016\/j.hrthm.2017.06.025; PMID: 28629852. DOI: 10.1016\/j.hrthm.2017.06.025","DOI":"10.1016\/j.hrthm.2017.06.025"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Gardner RT, Habecker BA. Infarct-derived chondroitin sulfate proteoglycans prevent sympathetic reinnervation after cardiac ischemia\u2013reperfusion injury. J Neurosci 2013;33:7175\u201383. https:\/\/doi.org\/10.1523\/JNEUROSCI.5866-12.2013; PMID: 23616527. DOI: 10.1523\/JNEUROSCI.5866-12.2013","DOI":"10.1523\/JNEUROSCI.5866-12.2013"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Gardner RT, Wang L, Lang BT, et al. Targeting protein tyrosine phosphatase sigma after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nat Commun 2015;6:6235. https:\/\/doi.org\/10.1038\/ncomms7235; PMID: 25639594. DOI: 10.1038\/ncomms7235","DOI":"10.1038\/ncomms7235"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Basile P, Monitillo F, Santoro D, et al. Impact on ventricular arrhythmic burden of SGLT2 inhibitors in patients with chronic heart failure evaluated with cardiac implantable electronic device monitoring. J Cardiol 2025;85:229\u201334. https:\/\/doi.org\/10.1016\/j.jjcc.2024.09.005; PMID: 39278346. DOI: 10.1016\/j.jjcc.2024.09.005","DOI":"10.1016\/j.jjcc.2024.09.005"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Liao J, Ebrahimi R, Ling Z, et al. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of >80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death). Cardiovasc Diabetol 2024;23:78. https:\/\/doi.org\/10.1186\/s12933-024-02137-x; PMID: 38402177. DOI: 10.1186\/s12933-024-02137-x","DOI":"10.1186\/s12933-024-02137-x"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 2020;19:148. https:\/\/doi.org\/10.1186\/s12933-020-01127-z; PMID: 32977831. DOI: 10.21203\/rs.3.rs-35207\/v1","DOI":"10.21203\/rs.3.rs-35207\/v1"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Herat LY, Magno AL, Rudnicka C, et al. SGLT2 Inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci 2020;5:169\u201379. https:\/\/doi.org\/10.1016\/j.jacbts.2019.11.007; PMID: 32140623. DOI: 10.1016\/j.jacbts.2019.11.007","DOI":"10.1016\/j.jacbts.2019.11.007"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004; PMID: 32613148. DOI: 10.1016\/j.jacbts.2020.02.004","DOI":"10.1016\/j.jacbts.2020.02.004"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Matthews VB, Elliot RH, Rudnicka C, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 2017;35:2059\u201368. https:\/\/doi.org\/10.1097\/HJH.0000000000001434; PMID: 28598954. DOI: 10.1097\/HJH.0000000000001434","DOI":"10.1097\/HJH.0000000000001434"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Sano M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis 2020;14:1753944720939383. https:\/\/doi.org\/10.1177\/1753944720939383; PMID: 32715944. DOI: 10.1177\/1753944720939383","DOI":"10.1177\/1753944720939383"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Herring N, Kalla M, Paterson DJ. The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies. Nat Rev Cardiol 2019;16:707\u201326. https:\/\/doi.org\/10.1038\/s41569-019-0221-2; PMID: 31197232. DOI: 10.1038\/s41569-019-0221-2","DOI":"10.1038\/s41569-019-0221-2"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Liu K, Li D, Hao G, et al. Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity. JCI Insight 2018;3:e98694. https:\/\/doi.org\/10.1172\/jci.insight.98694; PMID: 29720569. DOI: 10.1172\/jci.insight.98694","DOI":"10.1172\/jci.insight.98694"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Chang KC, Barth AS, Sasano T, et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci USA 2008;105:4477\u201382. https:\/\/doi.org\/10.1073\/pnas.0709118105; PMID: 18337493. DOI: 10.1073\/pnas.0709118105","DOI":"10.1073\/pnas.0709118105"}],"container-title":["Arrhythmia &amp; Electrophysiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2025.24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:23:38Z","timestamp":1766402618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2025.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":124,"URL":"https:\/\/doi.org\/10.15420\/aer.2025.24","relation":{},"ISSN":["2050-3369","2050-3377"],"issn-type":[{"value":"2050-3369","type":"print"},{"value":"2050-3377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"article-number":"e34"}}